company background image
DIA

DiaSorinBIT:DIA Stock Report

Last Price

€142.85

Market Cap

€7.8b

7D

-2.2%

1Y

-18.4%

Updated

21 Jan, 2022

Data

Company Financials +
DIA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance5/6
Financial Health3/6
Dividends4/6

DIA Stock Overview

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostic and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.

DiaSorin Competitors

Johnson & Johnson

NYSE:JNJ

US$434.0b

Roche Holding

SWX:ROG

CHF291.8b

Abbott Laboratories

NYSE:ABT

US$215.8b

Danaher

NYSE:DHR

US$200.4b

Price History & Performance

Summary of all time highs, changes and price drops for DiaSorin
Historical stock prices
Current Share Price€142.85
52 Week High€208.80
52 Week Low€133.30
Beta0.016
1 Month Change-11.74%
3 Month Change-24.38%
1 Year Change-18.37%
3 Year Change77.67%
5 Year Change157.16%
Change since IPO1,053.88%

Recent News & Updates

Jan 19
Is DiaSorin S.p.A. (BIT:DIA) Expensive For A Reason? A Look At Its Intrinsic Value

Is DiaSorin S.p.A. (BIT:DIA) Expensive For A Reason? A Look At Its Intrinsic Value

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of DiaSorin S.p.A...

Dec 04
Is DiaSorin (BIT:DIA) Using Too Much Debt?

Is DiaSorin (BIT:DIA) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Oct 18
Does DiaSorin (BIT:DIA) Deserve A Spot On Your Watchlist?

Does DiaSorin (BIT:DIA) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Aug 23
Is DiaSorin (BIT:DIA) A Risky Investment?

Is DiaSorin (BIT:DIA) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

DIAIT Medical EquipmentIT Market
7D-2.2%-2.2%-1.4%
1Y-18.4%4.4%20.8%

Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned 7.4% over the past year.

Return vs Market: DIA underperformed the Italian Market which returned 21.4% over the past year.

Price Volatility

Is DIA's price volatile compared to industry and market?
DIA volatility
DIA Average Weekly Movement5.7%
Medical Equipment Industry Average Movement6.4%
Market Average Movement4.3%
10% most volatile stocks in IT Market7.1%
10% least volatile stocks in IT Market2.7%

Stable Share Price: DIA is more volatile than 75% of Italian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: DIA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

FoundedEmployeesCEOWebsite
19682,104Carlo Rosahttps://www.diasoringroup.com

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostic and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. It provides various immunodiagnostic platforms, including LIAISON, LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform, comprising of LIAISON MDX. DiaSorin S.p.A. has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of Point-of-Care molecular platform; and MeMed for the launch of a test differentiating between viral and bacterial infections.

DiaSorin Fundamentals Summary

How do DiaSorin's earnings and revenue compare to its market cap?
DIA fundamental statistics
Market Cap€7.82b
Earnings (TTM)€314.67m
Revenue (TTM)€1.13b

24.8x

P/E Ratio

6.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DIA income statement (TTM)
Revenue€1.13b
Cost of Revenue€367.00m
Gross Profit€763.11m
Expenses€448.43m
Earnings€314.67m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)5.75
Gross Margin67.53%
Net Profit Margin27.84%
Debt/Equity Ratio8.8%

How did DIA perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

17%

Payout Ratio

Valuation

Is DiaSorin undervalued compared to its fair value and its price relative to the market?

24.84x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DIA (€142.85) is trading above our estimate of fair value (€111.61)

Significantly Below Fair Value: DIA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DIA is good value based on its PE Ratio (24.8x) compared to the European Medical Equipment industry average (32.5x).

PE vs Market: DIA is poor value based on its PE Ratio (24.8x) compared to the Italian market (19.4x).


Price to Earnings Growth Ratio

PEG Ratio: DIA is poor value based on its PEG Ratio (13.9x)


Price to Book Ratio

PB vs Industry: DIA is overvalued based on its PB Ratio (6.3x) compared to the XE Medical Equipment industry average (4.4x).


Future Growth

How is DiaSorin forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

1.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIA's forecast earnings growth (1.8% per year) is above the savings rate (1.8%).

Earnings vs Market: DIA's earnings (1.8% per year) are forecast to grow slower than the Italian market (11% per year).

High Growth Earnings: DIA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIA's revenue (5% per year) is forecast to grow faster than the Italian market (-0.1% per year).

High Growth Revenue: DIA's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIA's Return on Equity is forecast to be low in 3 years time (19.5%).


Past Performance

How has DiaSorin performed over the past 5 years?

20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIA has high quality earnings.

Growing Profit Margin: DIA's current net profit margins (27.8%) are higher than last year (26.7%).


Past Earnings Growth Analysis

Earnings Trend: DIA's earnings have grown significantly by 20.1% per year over the past 5 years.

Accelerating Growth: DIA's earnings growth over the past year (48.8%) exceeds its 5-year average (20.1% per year).

Earnings vs Industry: DIA earnings growth over the past year (48.8%) underperformed the Medical Equipment industry 62.2%.


Return on Equity

High ROE: DIA's Return on Equity (25.4%) is considered high.


Financial Health

How is DiaSorin's financial position?


Financial Position Analysis

Short Term Liabilities: DIA's short term assets (€-702.0M) do not cover its short term liabilities (€154.6M).

Long Term Liabilities: DIA's short term assets (€-702.0M) do not cover its long term liabilities (€108.8M).


Debt to Equity History and Analysis

Debt Level: DIA's net debt to equity ratio (93.2%) is considered high.

Reducing Debt: DIA's debt to equity ratio has reduced from 10.2% to 8.8% over the past 5 years.

Debt Coverage: DIA's debt is well covered by operating cash flow (373.5%).

Interest Coverage: DIA's interest payments on its debt are well covered by EBIT (34.5x coverage).


Balance Sheet


Dividend

What is DiaSorin current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DIA's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the Italian market (1.03%).

High Dividend: DIA's dividend (0.7%) is low compared to the top 25% of dividend payers in the Italian market (3.44%).


Stability and Growth of Payments

Stable Dividend: DIA's dividends per share have been stable in the past 10 years.

Growing Dividend: DIA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (17.4%), DIA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: DIA's dividends in 3 years are forecast to be well covered by earnings (23.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Carlo Rosa (55 yo)

16yrs

Tenure

€1,959,088

Compensation

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa l...


CEO Compensation Analysis

Compensation vs Market: Carlo's total compensation ($USD2.22M) is about average for companies of similar size in the Italian market ($USD1.84M).

Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DIA's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: DIA's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DiaSorin S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: DiaSorin S.p.A.
  • Ticker: DIA
  • Exchange: BIT
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €7.817b
  • Shares outstanding: 54.72m
  • Website: https://www.diasoringroup.com

Number of Employees


Location

  • DiaSorin S.p.A.
  • Via Crescentino snc
  • Saluggia
  • Vercelli
  • 13040
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 21:16
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.